1. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras^G12D-LSL mice

   • Brett H. Simmons
   • Joseph H. Lee
   • Farbod Shojaei

   Original Article 09 June 2012 Pages: 213 - 220

   

2. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells

   • Tobias Bartscht
   • Hendrik Lehnert
   • Hendrik Ungefroren

   Original Article 15 June 2012 Pages: 221 - 230

   

3. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters

   • Geoffrey Y. Ku
   • Benjamin A. Haaland
   • Gilberto de Lima Lopes Jr.

   Original Article 15 June 2012 Pages: 231 - 238

   

4. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors

   • Iñaki F. Trocóniz
   • Josep-María Cendrós
   • Rosendo Obach

   Original Article 15 June 2012 Pages: 239 - 250

   

5. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

   • John H. Strickler
   • Alexander N. Starodub
   • Herbert I. Hurwitz

   Original Article 29 June 2012 Pages: 251 - 258

   

6. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080

   • Foxiao Qiao
   • Daiying Zuo
   • Yingliang Wu

   Original Article 30 June 2012 Pages: 259 - 270

   

7. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902

   • Young Hak Kim
   • Masataka Hirabayashi
   • Michiaki Mishima

   Original Article 30 June 2012 Pages: 271 - 276

   

8. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer

   • Sun Jin Sym
   • Junsik Hong
   • Dong Bok Shin

   Original Article 30 June 2012 Pages: 277 - 284

   

9. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer

   • Sotaro Sadahiro
   • Toshiyuki Suzuki
   • Junji Uchida

   Original Article 30 June 2012 Pages: 285 - 291

   

10. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer

    • Feby Mardjuadi
    • Jacques Medioni
    • Jean-Pascal Machiels

    Original Article 01 July 2012 Pages: 293 - 303

    

11. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

    • A. W. Tolcher
    • K. N. Chi
    • N. Tran

    Original Article Open access 03 July 2012 Pages: 305 - 313

    

12. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation

    • Su-Hee Cho
    • Lee Chun Park
    • Myung-Ju Ahn

    Original Article 04 July 2012 Pages: 315 - 320

    

13. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase

    • Eric J. Sorscher
    • Jeong S. Hong
    • William B. Parker

    Original Article 04 July 2012 Pages: 321 - 329

    

14. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer

    • Masataka Yoshimoto
    • Shintaro Takao
    • Junichi Sakamoto

    Clinical Trial Report 11 April 2012 Pages: 331 - 338

    

15. Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1

    • Abhijit M. Godbole
    • Puranik Purushottamachar
    • Vincent C. O. Njar

    Short Communication 13 May 2012 Pages: 339 - 344

    

16. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

    • Ophelia Q. P. Yin
    • Frank J. Giles
    • Richard A. Larson

    Short Communication 24 May 2012 Pages: 345 - 350

    

17. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia

    • Akihito Matsuoka
    • Naoto Takahashi
    • Kenichi Sawada

    Letter to the Editor 08 June 2012 Pages: 351 - 352